NCT06835569View on ClinicalTrials.gov

A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations

PHASE1RecruitingINTERVENTIONAL
Enrollment

130

Participants

Timeline

Start Date

March 5, 2025

Primary Completion Date

May 31, 2029

Study Completion Date

August 31, 2029

Conditions
CancerPDAC - Pancreatic Ductal AdenocarcinomaNSCLC (Non-small Cell Lung Cancer)CRC (Colorectal Cancer)Advanced Solid Tumors
Interventions
DRUG

ALTA3263

Oral ALTA3263 tablets will be administered at a protocol-defined dose

Trial Locations (7)

10016

RECRUITING

Research Site, New York

22031

RECRUITING

Research Site, Fairfax

37203

RECRUITING

Research Site, Nashville

77030

RECRUITING

Research Site, Houston

78229

RECRUITING

Research Site, San Antonio

02114

RECRUITING

Research Site, Boston

02115

RECRUITING

Research Site, Boston

Sponsors
All Listed Sponsors
lead

Alterome Therapeutics, Inc.

INDUSTRY

NCT06835569 - A Study to Learn About Study Medicine ALTA3263 in Adults With Advanced Solid Tumors With KRAS Mutations | Biotech Hunter | Biotech Hunter